Neuroscience, Cholinergic, Nucleus basalis, Internal medicine and Audiology are his primary areas of study. His Cholinergic research is multidisciplinary, relying on both Cerebral cortex, Hippocampus and Muscarinic acetylcholine receptor. His studies deal with areas such as Lesion and Ibotenic acid as well as Nucleus basalis.
Internal medicine and Endocrinology are frequently intertwined in his study. His research integrates issues of Stimulus control and Developmental psychology in his study of Audiology. His work in Basal forebrain addresses subjects such as Memory Dysfunction, which are connected to disciplines such as Central nervous system.
His scientific interests lie mostly in Neuroscience, Internal medicine, Pharmacology, Endocrinology and Cholinergic. His Neuroscience research includes elements of Alzheimer's disease, Neurotrophic factors and Neurturin. Raymond T. Bartus combines subjects such as Clinical trial, Bioinformatics and Disease with his study of Neurotrophic factors.
His research investigates the connection with Neurturin and areas like Striatum which intersect with concerns in Substantia nigra. His work deals with themes such as Agonist, Central nervous system, Blood–brain barrier and Bradykinin, which intersect with Pharmacology. In his study, which falls under the umbrella issue of Cholinergic, Piracetam is strongly linked to Choline.
Raymond T. Bartus focuses on Neurturin, Neurotrophic factors, Neuroscience, Parkinson's disease and Substantia nigra. His Neurturin research incorporates elements of Striatum, Adverse effect and Genetic enhancement. His Neurotrophic factors research integrates issues from Clinical trial, Disease and Pharmacology.
Raymond T. Bartus is interested in Neuroprotection, which is a branch of Neuroscience. As part of the same scientific family, Raymond T. Bartus usually focuses on Substantia nigra, concentrating on Putamen and intersecting with Pathology. The study incorporates disciplines such as Endocrinology and Oncology in addition to Internal medicine.
His primary areas of study are Neurturin, Substantia nigra, Parkinson's disease, Neurotrophic factors and Neuroscience. His Neurturin study is focused on Internal medicine in general. His research integrates issues of Striatum and Putamen in his study of Substantia nigra.
His study looks at the relationship between Parkinson's disease and fields such as Pharmacology, as well as how they intersect with chemical problems. His study in Neuroscience concentrates on Pars compacta and Dopamine. His Adverse effect research is multidisciplinary, incorporating elements of Clinical endpoint, Clinical trial, Randomized controlled trial, Disease and Sham surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Cholinergic Hypothesis of Geriatric Memory Dysfunction
Raymond T. Bartus;Raymond T. Bartus;Reginald L. Dean;Bernard Beer;Bernard Beer;Arnold S. Lippa;Arnold S. Lippa.
Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work group
Thomas Crook;Raymond T. Bartus;Steven H. Ferris;Peter J. Whitehouse.
Developmental Neuropsychology (1986)
On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.
Raymond T. Bartus.
Experimental Neurology (2000)
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Jeffrey H. Kordower;C. Warren Olanow;Hemraj B. Dodiya;Yaping Chu.
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J Marks;Jill L Ostrem;Leonard Verhagen;Philip A Starr.
Lancet Neurology (2008)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
William J Marks;Raymond T Bartus;Joao Siffert;Charles S Davis.
Lancet Neurology (2010)
The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions
Raymond T. Bartus;Reginald L. Dean;Michael J. Pontecorvo;Charles Flicker.
Annals of the New York Academy of Sciences (1985)
Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat.
Charles Flicker;Reginald L. Dean;Dorothy L. Watkins;Stephen K. Fisher.
Pharmacology, Biochemistry and Behavior (1983)
Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine.
Raymond T. Bartus;H.R. Johnson.
Pharmacology, Biochemistry and Behavior (1976)
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
Keiro Ikeda;Tomotsugu Ichikawa;Hiroaki Wakimoto;Jonathan S. Silver.
Nature Medicine (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: